HSDT
Solana Company
Medical - Devices
Market Cap$87M
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
HSDT vs NVCR
Revenue, margins, valuation, and 5-year total return — side by side.
NVCR
NovoCure Limited
Medical - Instruments & Supplies
Market Cap$1.92B
5Y Perf.-75.0%
HSDT vs NVCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | HSDT | NVCR |
|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $87M | $1.92B |
| Revenue (TTM) | $6M | $674M |
| Net Income (TTM) | $-41M | $-173M |
| Gross Margin | 91.7% | 75.2% |
| Operating Margin | -351.0% | -27.2% |
| Total Debt | $0.00 | $290M |
| Cash & Equiv. | $7M | $103M |
HSDT vs NVCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
HSDT
NVCR
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Solana Company (HSDT) | 100 | 0.0 | -100.0% |
| NovoCure Limited (NVCR) | 100 | 25.0 | -75.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HSDT vs NVCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NVCR leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Solana Company is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
HSDT
Solana Company
The Growth Play
HSDT is the clearest fit if your priority is growth exposure.
- Rev growth 10.6%, EPS growth 57.3%, 3Y rev CAGR 97.0%
- 10.6% revenue growth vs NVCR's 8.3%
Best for: growth exposure
NVCR
NovoCure Limited
The Income Pick
NVCR carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 2.20
- 30.3% 10Y total return vs HSDT's -100.0%
- Lower volatility, beta 2.20, Low D/E 85.2%, current ratio 2.90x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | HSDT | 10.6% revenue growth vs NVCR's 8.3% |
| Quality / Margins | NVCR | -25.7% margin vs HSDT's -6.8% |
| Stability / Safety | NVCR | Beta 2.20 vs HSDT's 2.77 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NVCR | +1.1% vs HSDT's -99.0% |
| Efficiency (ROA) | NVCR | -16.5% ROA vs HSDT's -20.7%, ROIC -16.4% vs -10.8% |
HSDT vs NVCR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
HSDT vs NVCR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNVCRLAGGINGHSDT
HSDTSolana Company
1leads
NVCRNovoCure Limited
3leads
6 Total Categories
CATEGORYLEADERvs HSDTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
NVCR2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
HSDT5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
NVCR6/6
Risk & VolatilityBeta, volatility, and downside exposure
NVCR2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — HSDT and NVCR each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NVCR is the larger business by revenue, generating $674M annually — 112.1x HSDT's $6M. Profitability is closely matched — net margins range from -25.7% (NVCR) to -6.8% (HSDT). On growth, HSDT holds the edge at +33.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | HSDTSolana Company | NVCRNovoCure Limited |
|---|---|---|
| RevenueTrailing 12 months | $6M | $674M |
| EBITDAEarnings before interest/tax | -$21M | -$165M |
| Net IncomeAfter-tax profit | -$41M | -$173M |
| Free Cash FlowCash after capex | -$17M | -$48M |
| Gross MarginGross profit ÷ Revenue | +91.7% | +75.2% |
| Operating MarginEBIT ÷ Revenue | -3.5% | -27.2% |
| Net MarginNet income ÷ Revenue | -6.8% | -25.7% |
| FCF MarginFCF ÷ Revenue | -2.7% | -7.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +33.4% | +12.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.9% | -100.0% |
Evenly matched — HSDT and NVCR each lead in 3 of 6 comparable metrics.
Valuation Metrics
NVCR leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | HSDTSolana Company | NVCRNovoCure Limited |
|---|---|---|
| Market CapShares × price | $87M | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $79M | $2.1B |
| Trailing P/EPrice ÷ TTM EPS | -1.16x | -13.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 14.40x | 2.92x |
| Price / BookPrice ÷ Book value/share | 0.16x | 5.51x |
| Price / FCFMarket cap ÷ FCF | — | — |
NVCR leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
HSDT leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
NVCR delivers a -50.8% return on equity — every $100 of shareholder capital generates $-51 in annual profit, vs $-105 for HSDT. On the Piotroski fundamental quality scale (0–9), NVCR scores 5/9 vs HSDT's 4/9, reflecting solid financial health.
| Metric | HSDTSolana Company | NVCRNovoCure Limited |
|---|---|---|
| ROE (TTM)Return on equity | -105.0% | -50.8% |
| ROA (TTM)Return on assets | -20.7% | -16.5% |
| ROICReturn on invested capital | -10.8% | -16.4% |
| ROCEReturn on capital employed | -14.0% | -28.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 |
| Debt / EquityFinancial leverage | — | 0.85x |
| Net DebtTotal debt minus cash | -$7M | $187M |
| Cash & Equiv.Liquid assets | $7M | $103M |
| Total DebtShort + long-term debt | $0 | $290M |
| Interest CoverageEBIT ÷ Interest expense | -63.39x | -96.80x |
HSDT leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
NVCR leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NVCR five years ago would be worth $875 today (with dividends reinvested), compared to $0 for HSDT. Over the past 12 months, NVCR leads with a +1.1% total return vs HSDT's -99.0%. The 3-year compound annual growth rate (CAGR) favors NVCR at -37.6% vs HSDT's -92.9% — a key indicator of consistent wealth creation.
| Metric | HSDTSolana Company | NVCRNovoCure Limited |
|---|---|---|
| YTD ReturnYear-to-date | -30.4% | +28.3% |
| 1-Year ReturnPast 12 months | -99.0% | +1.1% |
| 3-Year ReturnCumulative with dividends | -100.0% | -75.7% |
| 5-Year ReturnCumulative with dividends | -100.0% | -91.3% |
| 10-Year ReturnCumulative with dividends | -100.0% | +30.3% |
| CAGR (3Y)Annualised 3-year return | -92.9% | -37.6% |
NVCR leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
NVCR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
NVCR is the less volatile stock with a 2.20 beta — it tends to amplify market swings less than HSDT's 2.77 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs HSDT's 0.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | HSDTSolana Company | NVCRNovoCure Limited |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.77x | 2.20x |
| 52-Week HighHighest price in past year | $258.50 | $20.06 |
| 52-Week LowLowest price in past year | $1.61 | $9.82 |
| % of 52W HighCurrent price vs 52-week peak | +0.8% | +83.9% |
| RSI (14)Momentum oscillator 0–100 | 58.6 | 69.8 |
| Avg Volume (50D)Average daily shares traded | 306K | 1.5M |
NVCR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | HSDTSolana Company | NVCRNovoCure Limited |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $33.50 |
| # AnalystsCovering analysts | — | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NVCR leads in 3 of 6 categories (Valuation Metrics, Total Returns). HSDT leads in 1 (Profitability & Efficiency). 1 tied.
Best OverallNovoCure Limited (NVCR)Leads 3 of 6 categories
Loading custom metrics...
HSDT vs NVCR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is HSDT or NVCR a better buy right now?
For growth investors, Solana Company (HSDT) is the stronger pick with 1057% revenue growth year-over-year, versus 8.
3% for NovoCure Limited (NVCR). Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — HSDT or NVCR?
Over the past 5 years, NovoCure Limited (NVCR) delivered a total return of -91.
3%, compared to -100. 0% for Solana Company (HSDT). Over 10 years, the gap is even starker: NVCR returned +30. 3% versus HSDT's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — HSDT or NVCR?
By beta (market sensitivity over 5 years), NovoCure Limited (NVCR) is the lower-risk stock at 2.
20β versus Solana Company's 2. 77β — meaning HSDT is approximately 26% more volatile than NVCR relative to the S&P 500.
04Which is growing faster — HSDT or NVCR?
By revenue growth (latest reported year), Solana Company (HSDT) is pulling ahead at 1057% versus 8.
3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: Solana Company grew EPS 57. 3% year-over-year, compared to 21. 8% for NovoCure Limited. Over a 3-year CAGR, HSDT leads at 97. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — HSDT or NVCR?
NovoCure Limited (NVCR) is the more profitable company, earning -20.
8% net margin versus -679. 6% for Solana Company — meaning it keeps -20. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVCR leads at -23. 5% versus -351. 0% for HSDT. At the gross margin level — before operating expenses — HSDT leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — HSDT or NVCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is HSDT or NVCR better for a retirement portfolio?
For long-horizon retirement investors, NovoCure Limited (NVCR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.
Solana Company (HSDT) carries a higher beta of 2. 77 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NVCR: +30. 3%, HSDT: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between HSDT and NVCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: HSDT is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(HSDT: 3339.5% · NVCR: 12.3%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.